-

ERS Genomics Announces Agreement With Applied StemCell to Commercialize CRISPR Gene Editing Services and Reagents

DUBLIN & MILPITAS, Calif.--(BUSINESS WIRE)--ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents and genetically modified cell lines and organisms.

Applied StemCell is a fast growing California based biotech company with a goal of advancing gene editing and stem cell innovation worldwide. Applied StemCell offers a wide variety of preclinical research services including cell and animal model generation, antibody discovery, and preclinical assay services to support cell/gene product development.

“Applied StemCell has been a leading stem cell company I have followed for many years," stated Eric Rhodes, CEO of ERS Genomics. “It is exciting to see their expertise in cell and animal models being combined with the power of CRISPR gene editing."

“We are extremely excited to build on the strength of our existing platform while investing our R&D in emerging technologies to drive our future growth,” stated Ruby Tsai, CEO of Applied StemCell.

Financial details of the agreement are not disclosed.

For a high-resolution image please contact Zyme Communications.

Contacts

Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com

Industry:

ERS Genomics Limited

Release Summary
ERS Genomics announces agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents
Release Versions
English

Contacts

Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com

More News From ERS Genomics Limited

ERS Genomics and Université de Montréal Sign CRISPR/Cas9 License Agreement

DUBLIN & MONTREAL--(BUSINESS WIRE)--ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants the university access to ERS’ CRISPR/Cas9 patent portfolio – including enabling the launch of two CRISPR/Cas9 screening facility platforms at UdeM's Institute for Research in Immunol...

ERS Genomics and Medicines Discovery Catapult Sign CRISPR/Cas9 License Agreement

DUBLIN, Ireland & MACCLESFIELD, England--(BUSINESS WIRE)--ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation centre, have signed a non-exclusive commercial-use CRISPR license agreement. The partnership combines ERS’s CRISPR/Cas9 patent portfolio with MDC’s world-class expertise and technology. MDC and its partners will benefit from access to ERS’ entire CRISPR/Cas9 portfolio – the foundat...

ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement

DUBLIN & ROME--(BUSINESS WIRE)--ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio. IRBM is a drug discovery CRO with expertise ranging from target validation and hit finding to preclinical candidate nomination across various therapeutic areas, including oncology, infectious diseases, and neuroscience. Th...
Back to Newsroom